Tempus AI TEM continues to expand its leadership in precision medicine through a series of impactful research initiatives and clinical validations. Throughout 2025 and early 2026, the company reported ...

Beyond diagnostics and data licensing, Tempus AI TEM is also focused on monetizing clinical applications and healthcare software designed for healthcare providers. The company is developing several ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

ADAM JAKUBIK is an economist in the IMF’s Strategy, Policy, and Review Department. ELIZABETH VAN HEUVELEN is a senior economist in the IMF’s Strategy, Policy, and Review Department. Opinions expressed ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

View post: 26-year-old local REI rival suddenly closing View post: Stock Market Today (Mar. 27, 2026): Dow Jones enters correction territory after nearly 800 decline on Iran jitters ...

Yesterday investors watched to see whether Tempus AI’s full-year and Q4 2025 results would validate the profitability story that the… ...